Lexiscan, Rapiscan(regadenoson)
Lexiscan, Rapiscan, Regadenoson (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A3, adenosine receptor A1, and adenosine receptor A2b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Lexiscan, Regadenoson
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Regadenoson
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEXISCAN | Astellas Pharma | N-022161 RX | 2008-04-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lexiscan | New Drug Application | 2018-12-21 |
| lexiscan(r) (regadenoson) | New Drug Application | 2024-01-28 |
| regadenoson | ANDA | 2025-12-08 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2785 | Injection, regadenoson, 0.1 mg |
Clinical
Clinical Trials
95 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 4 | 2 | 5 | 6 | 11 | 28 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 2 | 2 | 3 | 4 | 4 | 15 |
| Coronary disease | D003327 | — | — | 1 | 1 | 3 | 4 | 2 | 11 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | 1 | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | 1 | — | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | 1 | — | 2 |
| Obstructive lung diseases | D008173 | — | — | 1 | — | — | 1 | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 1 | 2 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | — | — | 1 | — | 1 |
| Graft rejection | D006084 | — | — | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial perfusion imaging | D055414 | — | — | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angina pectoris | D000787 | EFO_0003913 | I20 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 1 | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
| Chest pain | D002637 | — | R07.9 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Regadenoson |
| INN | regadenoson |
| Description | Regadenoson is a purine nucleoside. |
| Classification | Small molecule |
| Drug class | adenosine A receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O |
Identifiers
| PDB | — |
| CAS-ID | 313348-27-5 |
| RxCUI | 1546015 |
| ChEMBL ID | CHEMBL3989695 |
| ChEBI ID | — |
| PubChem CID | 219024 |
| DrugBank | DB06213 |
| UNII ID | 7AXV542LZ4 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,894 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,964 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use